| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)- Basic information |
| Product Name: | 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)- | | Synonyms: | 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)-;FT-4202;(S)-1-(5-((2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one;(S)-1-[5-[(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl]-5,6-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl]-3-hydroxy-2-phenyl-1-propanone;Etavopivat;(2S)-1-[5-[(2,3-Dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-1-propanone (ACI) | | CAS: | 2245053-57-8 | | MF: | C22H23N3O6S | | MW: | 457.5 | | EINECS: | | | Product Categories: | | | Mol File: | 2245053-57-8.mol | ![1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)- Structure](CAS/20210111/GIF/2245053-57-8.gif) |
| | 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)- Chemical Properties |
| Boiling point | 725.2±70.0 °C(Predicted) | | density | 1.53±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 14.27±0.10(Predicted) | | color | White to off-white |
| | 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)- Usage And Synthesis |
| Uses | Etavopivat is a potent, selective, and orally active erythrocyte pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects that can be used in studies of sickle cell disease and other haemoglobinopathies[1][2]. | | in vivo | Etavopivat (500-1000 mg/kg, p.o., daily, 2 weeks) improves RBC survival and Hb levels in SCA mice[1].
Etavopivat (3-22 mg/kg, p.o., daily, 5 days) causes an increase in 2,3-DPG and ATP in crab-eating monkeys at doses of 8 mg/kg and 22 mg/kg[2].
| Animal Model: | SCA mice[1] | | Dosage: | 500-1000 mg/kg | | Administration: | p.o., daily, 2 weeks | | Result: | Decreased the levels of 2,3-DPG.
Increased ATP levels.
Reduced sickling in vivo.
|
| | References | [1] Shrestha A, et al. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Blood Adv. 2021 May 11;5(9):2385-2390. DOI:10.1182/bloodadvances.2020003604 [2] Schroeder P, et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219. DOI:10.1124/jpet.121.000743 |
| | 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)- Preparation Products And Raw materials |
|